Aparito Limited

Aparito Limited is a United Kingdom digital health company based in Wrexham, Wales, that digitizes clinical trials and captures real-world data through its eCOA (electronic clinical outcome assessment) platform. The company was founded in 2014 by Dr. Elin Haf Davies with the aim of empowering patients in the drug development pathway and transforming how clinical studies are conducted and how novel eCOAs are developed. It was initially designed for rare diseases, where small, dispersed patient populations make traditional site-based trial participation difficult. Aparito's core offering is the Atom5™ eCOA platform, a full-stack system that combines video assessments, wearable devices, electronic patient-reported outcomes (ePROs), telemedicine and eConsent in one platform. The platform captures multiple, high-frequency data points from video, voice, wearables and ePRO, then leverages machine learning to provide rich, real-time insights to clinical teams. This allows studies to be carried out anytime and anywhere, enabling patients and their caregivers to participate in research both at the clinic and at home. The company positions itself around regulatory-grade data quality and security. According to its own materials, the Atom5™ platform is ISO 13485 / IEC 27001:2016 accredited and compliant with FDA 21 CFR Part 11, HIPAA and GDPR, and the company cites Cyber Essentials Plus and ISO 27001 credentials. Aparito also highlights a body of peer-reviewed publications (60+), reach across 193 countries and support for 125 languages, reflecting a global clinical research footprint. Aparito is a wholly owned subsidiary of Eli Lilly and Company. It remains registered in the UK under company number 09285366, with its registered office at Ty Dewi Sant, Rhosddu Road, Wrexham, Wales, LL11 1NF. The company operates in the clinical trial technology and real-world data segment, serving pharmaceutical sponsors, contract research organizations and research sites that need decentralized, patient-centric data capture.

Aparito Limited was founded in 2014 by Dr. Elin Haf Davies. The company was established with the mission of empowering patients in the drug development pathway and transforming how clinical studies are conducted and how novel electronic clinical outcome assessments (eCOAs) are developed. Its initial focus was on rare diseases, a therapeutic area where patients are often geographically dispersed and traditional site-based trial designs create significant participation barriers. To address this, Aparito built the Atom5™ eCOA platform, a full-stack system designed to allow studies to be carried out anytime and anywhere, enabling patients and their caregivers to participate in research both at the clinic and at home. The platform combines video assessments, wearable devices, electronic patient-reported outcomes (ePROs), telemedicine and eConsent, capturing multiple high-frequency data points from video, voice, wearables and ePRO, and then applying machine learning to deliver real-time insights to clinical teams. Over time, Aparito expanded its footprint in the clinical trial technology and real-world data market, supporting global studies. The company reports reach across 193 countries, support for 125 languages and more than 60 peer-reviewed publications arising from its work. It emphasizes regulatory-grade compliance and security, stating that the Atom5™ platform is ISO 13485 / IEC 27001:2016 accredited and compliant with FDA 21 CFR Part 11, HIPAA and GDPR, alongside Cyber Essentials Plus and ISO 27001 credentials. A significant turning point came when Aparito became a wholly owned subsidiary of Eli Lilly and Company. Under Lilly's ownership, Aparito continues to operate as a UK-registered company (company number 09285366) with its registered office at Ty Dewi Sant, Rhosddu Road, Wrexham, Wales, LL11 1NF. The company remains active in digitizing clinical trials and capturing real-world data for pharmaceutical sponsors, research organizations and sites.

• 2014

  Aparito was founded by Dr. Elin Haf Davies.

• Aparito became a wholly owned subsidiary of Eli Lilly and Company.

Regulatory-grade, patient-centric digital clinical trial and real-world data platform for decentralized research, initially focused on rare diseases and now serving global clinical studies.

• Atom5™ eCOA platform

  Full-stack electronic clinical outcome assessment platform combining video assessments, wearables, ePROs, telemedicine and eConsent, with machine learning for real-time insights.

1. 1Digitizing clinical trials | Aparitoaparito.com
2. 2About Aparito, a wholly owned subsidiary of Eli Lilly and Company | Aparitoaparito.com
3. 3Aparito Limited (United Kingdom) - Wikidatawikidata.org